ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu)…
DAHON Launches New Chapter: Grand Opening of DAGOLD Factory Paves the Way for Growth
TIANJIN, China, Oct. 16, 2025 /PRNewswire/ -- In response to the robust…
Medkart Champions Generic Drug Quality Amid Rising Consumer Concerns
With growing scrutiny around the quality and reliability of generic medicines in…
Rapid7 Celebrates 7th Year of Recognition in Gartner Magic Quadrant for Security Information and Event Management (SIEM)
BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a…
BYD improves Assisted Driving system in response to Euro NCAPs ATTO 3 grading
LEUVEN, BELGIUM – BYD has responded to the ’Not Recommended’ grading which…
Grounded Launches C1, Worlds First 500-Mile Range Hybrid Mobile Command Center at Climate Week NYC
Company also showcases public health and disaster response upfits, highlighting vehicle’s flexibility…
AV-Comparatives Publishes 2025 Endpoint Prevention & Response (EPR) Test – The Most Comprehensive Enterprise Cybersecurity Evaluation to Date
INNSBRUCK, Austria, Sept. 22, 2025 /PRNewswire/ -- AV-Comparatives, the leading independent cybersecurity…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET Â | Source: C4 Therapeutics, Inc. Cemsidomide in…